|
|
 Previous Article | Table of Contents | Next Article 
Polymorphism of adhesion molecule CD31 is not a significant risk factor for
graft-versus-host disease
WC Nichols, JH Antin, KL Lunetta, VH Terry, CE Hertel, MA Wheatley, ND Arnold, DR Siemieniak, M Boehnke and D Ginsburg
Department of Internal Medicine, University of Michigan Medical Center, Ann
Arbor 48109-0650, USA.
Mismatch between bone marrow transplant (BMT) patient and donor for an
amino acid polymorphism within the adhesion molecule CD31 has recently been
reported to increase risk for the development of graft-versus-host disease
(GVHD). We further examined this association in a larger series of 301 BMT
patients (227 with grade III/IV GVHD and 74 with grade 0 GVHD) and their
HLA-identical sibling donors. CD31 genotypes were determined by polymerase
chain reaction and restriction endonuclease digestion. The role of mismatch
at the CD31 locus in the development of GVHD was assessed by analyzing the
extent of CD31 identity and CD31 compatibility among the grade 0 GVHD and
grade III/IV GVHD sibling pairs. No significant association between CD31
mismatch and the development of severe GVHD was detected in our overall
patient population. Sixty-three percent of grade III/IV GVHD sibling pairs
and 69% of grade 0 GVHD sibling pairs had CD31 genotypes that were
identical (P = .36, odds ratio = 1.30). In addition, neither the grade 0
GVHD group (P = .10) nor the grade III/IV GVHD group (P = .27) differed
significantly from the expected probability of identity between sibling
pairs. Mismatch at the CD31 polymorphism between recipients and donors
showed no consistent association with the development of GVHD. Current
evidence does not support the value of CD31 mismatch in the selection of
BMT donors.
Volume 88,
Issue 12,
pp. 4429-4434,
12/15/1996
Copyright © 1996 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. J. Barrett, K. Rezvani, S. Solomon, A. M. Dickinson, X. N. Wang, G. Stark, H. Cullup, M. Jarvis, P. G. Middleton, and N. Chao
New Developments in Allotransplant Immunology
Hematology,
January 1, 2003;
2003(1):
350 - 371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kroll, Q.-H. Sun, and S. Santoso
Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a target glycoprotein in drug-induced thrombocytopenia
Blood,
August 15, 2000;
96(4):
1409 - 1414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Maruya, H. Saji, S. Seki, Y. Fujii, K. Kato, S. Kai, A. Hiraoka, K. Kawa, Y. Hoshi, K. Ito, et al.
Evidence That CD31, CD49b, and CD62L Are Immunodominant Minor Histocompatibility Antigens in HLA Identical Sibling Bone Marrow Transplants
Blood,
September 15, 1998;
92(6):
2169 - 2176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Da Costa, D. Charron, and P. Loiseau
Does the Adhesion Molecule CD31 Act as a Minor Histocompatibility Antigen?
Blood,
August 1, 1997;
90(3):
1332 - 1332.
[Full Text]
[PDF]
|
|
|
|
|
